<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
  <title>GIDS Research Radar · United States</title>
  <link>https://globalinfectiousdisease.com/research/</link>
  <description>Published infectious-disease literature filtered to United States.</description>
  <language>en</language>
  <atom:link href="https://globalinfectiousdisease.com/research/rss/countries/us.xml" rel="self" type="application/rss+xml" />
  <lastBuildDate>Wed, 09 Sep 2026 07:02:01 GMT</lastBuildDate>
  <item>
    <title>Post-marketing safety surveillance of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine: a disproportionality analysis of the vaccine adverse event reporting system (2015–2025)</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-3389-fcimb-2026-1831548-a72456c2/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-3389-fcimb-2026-1831548-a72456c2/</guid>
    <pubDate>Tue, 08 Sep 2026 00:00:00 GMT</pubDate>
    <description>The paper addresses post-marketing vaccine safety surveillance for a routinely recommended vaccine. Its relevance is strongest for safety signal detection and hypothesis generation in Tdap vaccination programs.</description>
    <category>Pertussis</category>
    <category>Diphtheria</category>
    <category>Tetanus</category>
    <category>Vaccination</category>
    <category>Surveillance</category>
    <category>Vaccine safety</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Timing, Titre, and Host Determinants of Convalescent Plasma Efficacy in COVID-19: A Systematic Review With Design-Stratified Narrative Synthesis.</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1002-rmv-70189-831219ed/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1002-rmv-70189-831219ed/</guid>
    <pubDate>Tue, 01 Sep 2026 00:00:00 GMT</pubDate>
    <description>Clarifying these operational parameters supports more precise therapeutic allocation and establishes a methodological framework for managing future infectious disease crises.</description>
    <category>SARS</category>
    <category>COVID-19</category>
    <category>Vaccination</category>
    <category>Treatment</category>
    <category>Transmission dynamics</category>
    <category>Systematic review</category>
  </item>
  <item>
    <title>2024–2025 BNT162b2 KP.2 COVID-19 full season vaccine effectiveness from vaccine registries linked to administrative claims in two states: A cohort study in non-immunocompromised adults</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-129009-9ffc71a1/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-129009-9ffc71a1/</guid>
    <pubDate>Tue, 01 Sep 2026 00:00:00 GMT</pubDate>
    <description>Findings support continued COVID-19 vaccine recommendations, demonstrating protection across the 2024-2025 season for adults including those with underlying medical conditions.</description>
    <category>COVID-19</category>
    <category>Influenza</category>
    <category>Vaccination</category>
    <category>Vaccine effectiveness</category>
    <category>Cohort study</category>
  </item>
  <item>
    <title>Using high frequency GPS data to assess wintering goose proximity to commercial poultry facilities on the Delmarva peninsula for avian influenza risk management and surveillance.</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1371-journal-pone-0355415-e4d17955/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1371-journal-pone-0355415-e4d17955/</guid>
    <pubDate>Tue, 01 Sep 2026 00:00:00 GMT</pubDate>
    <description>The findings describe a possible way to prioritize biosecurity or surveillance resources around poultry facilities using observed wintering-waterfowl presence. This is an evidence-context signal from the supplied article and does not establish that the ranking method is validated for current surveillance or outbreak prediction.</description>
    <category>Influenza</category>
    <category>H5N1</category>
    <category>Surveillance</category>
    <category>Outbreak investigation</category>
    <category>Treatment</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Clustering and Source Association of Clinical and Nonclinical Listeria monocytogenes Isolates, New York, USA, 2000-2021&lt;sup&gt;1&lt;/sup&gt;.</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-3201-eid3209-260289-07264e48/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-3201-eid3209-260289-07264e48/</guid>
    <pubDate>Tue, 01 Sep 2026 00:00:00 GMT</pubDate>
    <description>The authors suggest that whole-genome sequencing may strengthen outbreak investigation and source attribution for L. monocytogenes and that produce-associated transmission may reflect distinct pathways.</description>
    <category>Listeriosis</category>
    <category>Genomic epidemiology</category>
    <category>Outbreak investigation</category>
    <category>Surveillance</category>
    <category>Transmission dynamics</category>
    <category>Genomic study</category>
  </item>
  <item>
    <title>Deconvolving SARS-CoV-2 mRNA Vaccine Impact on Immunotherapy-Related Survival</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1158-2159-8290-cd-26-0403-4efecc0b/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1158-2159-8290-cd-26-0403-4efecc0b/</guid>
    <pubDate>Fri, 28 Aug 2026 00:00:00 GMT</pubDate>
    <description>Within the supplied cancer-care cohorts, the findings do not support interpreting peri-treatment SARS-CoV-2 mRNA vaccination as improving immunotherapy-related survival. The abstract describes the observed early-pandemic association as largely attributable to selection bias involving more favorable-prognosis patients.</description>
    <category>SARS</category>
    <category>COVID-19</category>
    <category>Vaccination</category>
    <category>Treatment</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Recombinant Influenza Vaccine and Influenza Outbreaks in US Nursing Homes: Results from a Pragmatic Cluster-Randomized Clinical Trial</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1093-ofid-ofag522-4f2a4986/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1093-ofid-ofag522-4f2a4986/</guid>
    <pubDate>Thu, 27 Aug 2026 00:00:00 GMT</pubDate>
    <description>The results suggest that deploying this specific immunization strategy may help curb institutional transmission episodes during years with active seasonal pathogen circulation, thereby potentially reducing operational disruptions within elderly care infrastructure.</description>
    <category>Influenza</category>
    <category>COVID-19</category>
    <category>Vaccination</category>
    <category>Treatment</category>
    <category>Outbreak investigation</category>
    <category>Transmission dynamics</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Hearing aids for mild to moderate hearing loss in adults</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1002-14651858-cd012023-pub3-623f5813/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1002-14651858-cd012023-pub3-623f5813/</guid>
    <pubDate>Wed, 26 Aug 2026 00:00:00 GMT</pubDate>
    <description>Findings align with routine first-line clinical provision of hearing aids to adults seeking help for hearing difficulties, while signalling ongoing uncertainty around benefits for mental health and cognition.</description>
    <category>AIDS</category>
    <category>Noise-induced hearing loss</category>
    <category>Treatment</category>
    <category>Climate and environment</category>
    <category>Systematic review</category>
  </item>
  <item>
    <title>Phylogenetic and phylogeographic analysis of equine influenza in Colombia.</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1002-evj-70314-8c1f8d64/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1002-evj-70314-8c1f8d64/</guid>
    <pubDate>Wed, 26 Aug 2026 00:00:00 GMT</pubDate>
    <description>The genetic proximity to foreign viral strains highlights cross-border animal trade as a potential introduction pathway, emphasizing the need for continuous genomic monitoring to track strain evolution and guide control measures.</description>
    <category>Influenza</category>
    <category>Genomic epidemiology</category>
    <category>Surveillance</category>
    <category>Outbreak investigation</category>
    <category>Transmission dynamics</category>
    <category>Genomic study</category>
  </item>
  <item>
    <title>Declining Gonorrhea Case Rates in the United States, 2021-2023: A Spatial Analysis.</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1016-j-annepidem-2026-110268-91028d3b/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1016-j-annepidem-2026-110268-91028d3b/</guid>
    <pubDate>Tue, 25 Aug 2026 00:00:00 GMT</pubDate>
    <description>These observations highlight persistent regional disparities in sexually transmitted infection burdens. Strategic planning may benefit from acknowledging that broad national improvements can occasionally obscure localized escalation in specific metropolitan zones.</description>
    <category>Gonorrhea</category>
    <category>Surveillance</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Tularemia: a re-emerging zoonosis.</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1016-j-medcli-2026-107565-28481b3b/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1016-j-medcli-2026-107565-28481b3b/</guid>
    <pubDate>Tue, 25 Aug 2026 00:00:00 GMT</pubDate>
    <description>Tularemia is classified as a CDC Category A bioterrorism agent due to extreme virulence (infection possible with as few as 10 cells) and 30% mortality in untreated cases. The documented re-emergence across multiple Northern Hemisphere regions underscores the need for updated clinical awareness and early diagnostic capacity.</description>
    <category>Tularemia</category>
    <category>Vaccination</category>
    <category>Genomic epidemiology</category>
    <category>Diagnostics</category>
    <category>Treatment</category>
    <category>Genomic study</category>
  </item>
  <item>
    <title>Safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered concomitantly with routine pediatric vaccines in healthy infants and toddlers in USA and Puerto Rico: Results from a Phase III, randomized, active-controlled study.</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1080-21645515-2026-2716508-f8e301e4/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1080-21645515-2026-2716508-f8e301e4/</guid>
    <pubDate>Tue, 25 Aug 2026 00:00:00 GMT</pubDate>
    <description>Establishing the safety of this vaccine when combined with routine pediatric immunizations aids regulatory approval and clinical administration guidelines. The data contributes to understanding potential interactions within standard infant vaccination protocols.</description>
    <category>Diphtheria</category>
    <category>Tetanus</category>
    <category>Pertussis</category>
    <category>Meningococcal disease</category>
    <category>Varicella</category>
    <category>Hepatitis B</category>
    <category>Vaccination</category>
    <category>Treatment</category>
    <category>Randomised controlled trial</category>
  </item>
  <item>
    <title>Emergence of alveolar echinococcosis in Canada: a warning for the USA</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1097-qco-0000000000001229-39e1e4e7/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1097-qco-0000000000001229-39e1e4e7/</guid>
    <pubDate>Mon, 24 Aug 2026 00:00:00 GMT</pubDate>
    <description>The authors describe alveolar echinococcosis as an emerging, under-recognized zoonotic disease in Canada and emphasize that early recognition using Em-specific diagnostics, along with a One Health approach integrating human, veterinary, and wildlife data, is needed to reduce morbidity and mortality.</description>
    <category>Echinococcosis</category>
    <category>Treatment</category>
    <category>One Health</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Management of neonates born to mothers with reactive serologic tests for syphilis</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1097-qco-0000000000001234-117d9b89/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1097-qco-0000000000001234-117d9b89/</guid>
    <pubDate>Mon, 24 Aug 2026 00:00:00 GMT</pubDate>
    <description>The review is framed around the U.S. resurgence of maternal and congenital syphilis, noting associated neonatal morbidity and mortality and calling for more practical, safe management approaches.</description>
    <category>Syphilis</category>
    <category>Congenital syphilis</category>
    <category>Syphilis in pregnancy</category>
    <category>Treatment</category>
    <category>Health policy</category>
    <category>Guideline</category>
  </item>
  <item>
    <title>Global, Regional and National Trends in Latent Tuberculosis Infection Prevalence From 1990 to 2023, With Projections to 2050</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-24976-discov-med-202638211-205-da1dffa9/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-24976-discov-med-202638211-205-da1dffa9/</guid>
    <pubDate>Mon, 24 Aug 2026 00:00:00 GMT</pubDate>
    <description>The authors argue that sustained declines in standardized LTBI rates co-exist with a growing absolute caseload, implying that TB elimination efforts require prevention-oriented policies targeting progression to active disease, especially in ageing and other high-risk populations.</description>
    <category>Tuberculosis</category>
    <category>Health policy</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Updated Assessment of the Impact of the Modified Council of State and Territorial Epidemiologists Case Definition for Pertussis on Reported Pertussis</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1093-cid-ciag515-2efdbca0/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1093-cid-ciag515-2efdbca0/</guid>
    <pubDate>Sat, 22 Aug 2026 00:00:00 GMT</pubDate>
    <description>The findings indicate that changes in the pertussis case definition affect interpretation of reported disease trends over time. The abstract describes the 2020 definition change as contributing to the magnitude of the reported 2024 increase.</description>
    <category>Pertussis</category>
    <category>COVID-19</category>
    <category>Surveillance</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Mapping the Surveillance Data Infrastructure in the U.S. for SARS-CoV-2, Influenza, and Respiratory Syncytial Virus</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1007-s40471-026-00405-w-511150c9/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1007-s40471-026-00405-w-511150c9/</guid>
    <pubDate>Fri, 21 Aug 2026 00:00:00 GMT</pubDate>
    <description>Clarifying the scope and availability of these monitoring frameworks may streamline epidemiological investigations and support more effective emergency management strategies.</description>
    <category>SARS</category>
    <category>COVID-19</category>
    <category>Influenza</category>
    <category>Surveillance</category>
    <category>Outbreak investigation</category>
    <category>Health policy</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Retrospective Analysis of Chronic Q Fever Cases at a Tertiary Care Center from 2007 to 2023</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1093-ofid-ofag542-e04c4d17/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1093-ofid-ofag542-e04c4d17/</guid>
    <pubDate>Fri, 21 Aug 2026 00:00:00 GMT</pubDate>
    <description>Chronic Q fever cases are increasing in the United States, often without identifiable exposures. Diagnostic delays remain common and may contribute to morbidity in patients with cardiac or vascular conditions.</description>
    <category>Q fever</category>
    <category>Diagnostics</category>
    <category>Treatment</category>
    <category>Cohort study</category>
  </item>
  <item>
    <title>Do Digital Visual Aids Improve Skin Self-Examination Behaviours? A Systematic Review</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1177-10901981261479324-f115e091/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1177-10901981261479324-f115e091/</guid>
    <pubDate>Fri, 21 Aug 2026 00:00:00 GMT</pubDate>
    <description>Skin self-examination represents a secondary prevention approach for early skin cancer detection. Digital visual aids such as smartphone applications may support broader uptake and maintenance of these examination behaviors.</description>
    <category>AIDS</category>
    <category>Systematic review</category>
  </item>
  <item>
    <title>A challenging presentation of central nervous system involvement in disseminated coccidioidomycosis: Insights from cases</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-25259-sni-613-2025-b0aa70e7/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-25259-sni-613-2025-b0aa70e7/</guid>
    <pubDate>Fri, 21 Aug 2026 00:00:00 GMT</pubDate>
    <description>CNS coccidioidomycosis is rare but challenging to diagnose due to imaging resemblance to malignancy or inflammation, highlighting the need for clinician awareness in endemic areas and early tissue-based diagnosis.</description>
    <category>Coccidioidomycosis</category>
    <category>Diagnostics</category>
    <category>Treatment</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Extending the Duration of Artemether-Lumefantrine Treatment for Uncomplicated Plasmodium falciparum Malaria: Updated US Centers for Disease Control and Prevention Guidance Based on Review of Surveillance, Consultations, and Published Data</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1093-cid-ciag456-d08fe121/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1093-cid-ciag456-d08fe121/</guid>
    <pubDate>Wed, 19 Aug 2026 00:00:00 GMT</pubDate>
    <description>The article provides evidence relevant to treatment policy for uncomplicated Plasmodium falciparum malaria among travelers in the United States. Its findings were reported as informing updated CDC guidance, but this summary does not independently assess that guidance or connect the article with a live surveillance signal.</description>
    <category>Malaria</category>
    <category>Plasmodium falciparum malaria</category>
    <category>Treatment</category>
    <category>Surveillance</category>
    <category>Travel medicine</category>
    <category>Meta-analysis</category>
  </item>
  <item>
    <title>County, district and community-level measles transmission in the United States in 2013−2025</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1038-s41591-026-04561-w-113aa29d/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1038-s41591-026-04561-w-113aa29d/</guid>
    <pubDate>Tue, 18 Aug 2026 00:00:00 GMT</pubDate>
    <description>The abstract indicates potential relevance for assessing measles vulnerability and for considering vaccination and outbreak-monitoring approaches at school and district levels. These implications are model-based and do not establish that a current surveillance signal has been confirmed.</description>
    <category>Measles</category>
    <category>COVID-19</category>
    <category>Transmission dynamics</category>
    <category>Vaccination</category>
    <category>Outbreak investigation</category>
    <category>Surveillance</category>
    <category>One Health</category>
    <category>Mathematical modelling</category>
  </item>
  <item>
    <title>Monkeypox virus clade IIb isolate exhibits reduced virulence relative to clade IIa isolates in multiple murine models</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1128-jvi-00247-26-5f2069b3/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1128-jvi-00247-26-5f2069b3/</guid>
    <pubDate>Tue, 18 Aug 2026 00:00:00 GMT</pubDate>
    <description>Validating these murine platforms facilitates ongoing research into viral mechanisms and supports the evaluation of potential therapeutic strategies against divergent orthopoxvirus lineages.</description>
    <category>Monkeypox</category>
    <category>Outbreak investigation</category>
    <category>Climate and environment</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>The bacterial pH gradient contributes to persistence in Mycobacterium tuberculosis</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1128-mbio-01692-26-283fceac/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1128-mbio-01692-26-283fceac/</guid>
    <pubDate>Tue, 18 Aug 2026 00:00:00 GMT</pubDate>
    <description>Findings suggest that pharmacological disruption of the bacterial pH gradient is a rapid chemical tool to study persister biology in TB, with potential broader relevance to other infectious diseases.</description>
    <category>Tuberculosis</category>
    <category>Treatment</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Serologic Immunity to Hepatitis A and B in US Adults and High-Risk Populations</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1001-jamainternmed-2026-3831-dca77f2e/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1001-jamainternmed-2026-3831-dca77f2e/</guid>
    <pubDate>Mon, 17 Aug 2026 00:00:00 GMT</pubDate>
    <description>Widespread susceptibility across multiple demographic and clinical strata suggests current immunization coverage falls short of optimal population thresholds. These results emphasize the necessity for focused preventive campaigns directed toward underserved and medically vulnerable communities.</description>
    <category>Hepatitis A</category>
    <category>Hepatitis B</category>
    <category>Viral Hepatitis</category>
    <category>Hepatitis D</category>
    <category>Vaccination</category>
    <category>Cross-sectional study</category>
  </item>
  <item>
    <title>Prenatal testing and postpartum treatment for hepatitis C virus among women with opioid use disorder</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1002-pmf2-70382-fb5d6fe1/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1002-pmf2-70382-fb5d6fe1/</guid>
    <pubDate>Mon, 17 Aug 2026 00:00:00 GMT</pubDate>
    <description>The observed discrepancies between recommended protocols and actual clinical practices indicate potential systemic barriers to standard care pathways for this demographic.</description>
    <category>Hepatitis E</category>
    <category>Hepatitis C</category>
    <category>Treatment</category>
    <category>Surveillance</category>
    <category>Diagnostics</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Meeting Patients with Hepatitis C Where They Are: Lessons from the HIV Epidemic in the USA</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1007-s11606-026-10629-7-b13e6dbd/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1007-s11606-026-10629-7-b13e6dbd/</guid>
    <pubDate>Mon, 17 Aug 2026 00:00:00 GMT</pubDate>
    <description>The article addresses national HCV eradication goals and advocates for equitable treatment access. It proposes a test-and-treat approach during hospital admission and reframing nonadherence as a need for support rather than a patient deficiency.</description>
    <category>Hepatitis C</category>
    <category>Hepatitis E</category>
    <category>Treatment</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Effectiveness of pharmacist-delivered vaccination recommendations for herpes zoster: a systematic review</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-3389-fpubh-2026-1884479-77962d08/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-3389-fpubh-2026-1884479-77962d08/</guid>
    <pubDate>Mon, 17 Aug 2026 00:00:00 GMT</pubDate>
    <description>Enhancing professional guidance within retail pharmacy settings may help mitigate persistent disease burden in aging populations by facilitating greater immunization participation.</description>
    <category>Zoster</category>
    <category>Vaccination</category>
    <category>Systematic review</category>
  </item>
  <item>
    <title>Clinical progress note: Hepatitis B</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1002-jhm-70424-fafda04a/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1002-jhm-70424-fafda04a/</guid>
    <pubDate>Sat, 15 Aug 2026 00:00:00 GMT</pubDate>
    <description>Shifting national immunization directives and growing vaccine reluctance emphasize the sustained requirement for vigilant epidemiological tracking and targeted pediatric intervention strategies.</description>
    <category>Hepatitis B</category>
    <category>Hepatitis D</category>
    <category>Transmission dynamics</category>
    <category>Vaccination</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Real-world analysis of depression-related adverse events associated with the adsorbed anthrax vaccine: integrating pharmacovigilance signals, machine learning risk prediction, and transcriptomic mechanisms</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1186-s40249-026-01483-0-c4194a40/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1186-s40249-026-01483-0-c4194a40/</guid>
    <pubDate>Mon, 10 Aug 2026 00:00:00 GMT</pubDate>
    <description>The documented reporting patterns indicate a rationale for strengthening psychiatric symptom tracking during post-vaccination windows and refining safety communications within biodefense preparedness programs.</description>
    <category>Anthrax</category>
    <category>Vaccination</category>
    <category>Vaccine safety</category>
    <category>Treatment</category>
    <category>One Health</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Evaluation of the effectiveness of artemether–lumefantrine and artesunate–pyronaridine each combined with single low-dose primaquine in adults with Plasmodium falciparum infection in Ethiopia: a phase 2/3, observer-masked, randomised, parallel-group trial</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1016-j-lanmic-2025-101344-b6e9fecd/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1016-j-lanmic-2025-101344-b6e9fecd/</guid>
    <pubDate>Sat, 01 Aug 2026 00:00:00 GMT</pubDate>
    <description>The data substantiate the sustained implementation of artemether-lumefantrine paired with primaquine while positioning the alternative pyronaridine-artesunate regimen as a reliable secondary option for areas confronting evolving drug resistance and diagnostic reliability concerns.</description>
    <category>Malaria</category>
    <category>Treatment</category>
    <category>Surveillance</category>
    <category>Diagnostics</category>
    <category>Randomised controlled trial</category>
  </item>
  <item>
    <title>Comparison of phylogenetic metrics of transmission between symptomatic and asymptomatic tuberculosis in individuals who were incarcerated in Brazil in 2008–24: a retrospective genomic epidemiology study</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1016-j-lanmic-2026-101407-4e147d53/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1016-j-lanmic-2026-101407-4e147d53/</guid>
    <pubDate>Sat, 01 Aug 2026 00:00:00 GMT</pubDate>
    <description>Exclusive reliance on clinical symptoms for identifying infected persons may overlook a major driver of ongoing dissemination, indicating that systematic screening protocols are essential in congregate environments.</description>
    <category>Tuberculosis</category>
    <category>Genomic epidemiology</category>
    <category>Transmission dynamics</category>
    <category>Surveillance</category>
    <category>Cohort study</category>
  </item>
  <item>
    <title>V-safe: Summary of findings reported after COVID-19 vaccination to a US CDC active safety surveillance system through June 2023</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128725-c1232c3d/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128725-c1232c3d/</guid>
    <pubDate>Sat, 01 Aug 2026 00:00:00 GMT</pubDate>
    <description>Continuous tracking of self-reported tolerability complements traditional clinical trial metrics and supports ongoing evaluation of emerging immunization products. Identifying engagement drop-offs informs strategy development for sustaining participant involvement during future public health emergencies.</description>
    <category>COVID-19</category>
    <category>SARS</category>
    <category>Vaccination</category>
    <category>Surveillance</category>
    <category>Vaccine safety</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Incidence of outcomes relevant to vaccine safety monitoring in the general population, after influenza vaccination, and after respiratory infections: a descriptive analysis of four US claims databases, 2022–2023</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128821-769efdf1/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128821-769efdf1/</guid>
    <pubDate>Sat, 01 Aug 2026 00:00:00 GMT</pubDate>
    <description>Contemporaneous incidence estimates for 30 safety outcomes across five organ systems can inform benefit-risk framing for new and existing respiratory vaccines during the COVID-19 endemic era and highlight the need to account for age and sex when interpreting expected rates.</description>
    <category>COVID-19</category>
    <category>Influenza</category>
    <category>SARS</category>
    <category>Vaccination</category>
    <category>Surveillance</category>
    <category>Vaccine safety</category>
    <category>Cohort study</category>
  </item>
  <item>
    <title>Vaccine uptake in the context of mandate announcement and removal: Evidence from Europe and North America</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128825-7a56d639/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128825-7a56d639/</guid>
    <pubDate>Sat, 01 Aug 2026 00:00:00 GMT</pubDate>
    <description>Regulatory measures appear capable of producing temporary shifts in immunization behavior, underscoring the value of strategic communication and phased implementation to preserve coverage during administrative changes.</description>
    <category>COVID-19</category>
    <category>SARS</category>
    <category>Vaccination</category>
    <category>Health policy</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Cross-sectional analysis of chikungunya vaccine acceptability among residents of Ponce, Puerto Rico, 2024–2025</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128845-e5eb952d/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128845-e5eb952d/</guid>
    <pubDate>Sat, 01 Aug 2026 00:00:00 GMT</pubDate>
    <description>Identifying regional vaccination preferences enables health authorities to develop targeted educational campaigns that address safety inquiries and potentially increase immunization coverage during future arboviral events.</description>
    <category>Chikungunya</category>
    <category>Vaccination</category>
    <category>Outbreak investigation</category>
    <category>Vaccine safety</category>
    <category>Cross-sectional study</category>
  </item>
  <item>
    <title>Caregiver COVID-19 vaccine status and its influence on pediatric vaccination decisions in a US cohort</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128847-1a3be2a6/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128847-1a3be2a6/</guid>
    <pubDate>Sat, 01 Aug 2026 00:00:00 GMT</pubDate>
    <description>The findings underscore how parental immunization perspectives shape broader pediatric preventive care patterns within American households.</description>
    <category>COVID-19</category>
    <category>SARS</category>
    <category>Vaccination</category>
    <category>Cohort study</category>
  </item>
  <item>
    <title>Vaccine effectiveness of mRNA-1345 against RSV-associated hospitalization and medically attended acute respiratory illness among US veterans, 2025–2026</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128882-ce2fe6ce/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128882-ce2fe6ce/</guid>
    <pubDate>Sat, 01 Aug 2026 00:00:00 GMT</pubDate>
    <description>The findings suggest mRNA-1345 provides substantial real-world protection against RSV-related hospitalization and healthcare utilization in older adults, supporting the vaccine&apos;s value for reducing RSV disease burden in high-risk populations.</description>
    <category>SARS</category>
    <category>COVID-19</category>
    <category>Vaccination</category>
    <category>Vaccine effectiveness</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Elected officials’ online anti-vaccination statements respond to online engagement</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128901-32f06a9d/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128901-32f06a9d/</guid>
    <pubDate>Sat, 01 Aug 2026 00:00:00 GMT</pubDate>
    <description>The findings describe associations between social-media engagement, legislators&apos; anti-vaccination communication, and links to low-credibility sources. The abstract places these patterns in the context of political communication and public-health governance.</description>
    <category>COVID-19</category>
    <category>Vaccination</category>
    <category>Health policy</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Australians&apos; attitudes to mRNA vaccination in humans and animals: A cross-sectional survey</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128907-dee036dc/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128907-dee036dc/</guid>
    <pubDate>Sat, 01 Aug 2026 00:00:00 GMT</pubDate>
    <description>The authors highlight the need for vaccine manufacturers and public- and animal-health policymakers to anticipate potentially lower public acceptance of mRNA vaccines and of animal-source foods derived from mRNA-vaccinated livestock, noting that scientific development must be matched by public acceptability for new vaccines to be optimally used.</description>
    <category>COVID-19</category>
    <category>SARS</category>
    <category>Vaccination</category>
    <category>Health policy</category>
    <category>Cross-sectional study</category>
  </item>
  <item>
    <title>Characteristics of successful and unsuccessful strategies to increase vaccine intention and improve vaccine uptake for U.S. adult populations in the Affordable Care Act era (2010-2025): a systematic review and meta-regression</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128910-5d095fe1/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128910-5d095fe1/</guid>
    <pubDate>Sat, 01 Aug 2026 00:00:00 GMT</pubDate>
    <description>Highlights how logistical and organizational modifications can address persistent immunization gaps even after financial barriers are removed.</description>
    <category>COVID-19</category>
    <category>Influenza</category>
    <category>Vaccination</category>
    <category>Systematic review</category>
  </item>
  <item>
    <title>Cost-effectiveness analysis of a hypothetical vaccine for schistosomiasis in Madagascar and Burkina Faso</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128936-0b54e812/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128936-0b54e812/</guid>
    <pubDate>Sat, 01 Aug 2026 00:00:00 GMT</pubDate>
    <description>The modeling results suggest that integrating adult demographics into future immunization campaigns could optimize resource allocation and disease reduction in highly affected regions. Policymakers might consider these economic parameters when planning next-generation preventive tools against this parasitic infection.</description>
    <category>Schistosomiasis</category>
    <category>Vaccination</category>
    <category>Vaccine effectiveness</category>
    <category>Treatment</category>
    <category>Health policy</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Duration and association with protection of NANP-repeat-specific and C-terminus-specific anti-circumsporozoite protein IgG responses following RTS,S/AS01E vaccination: an observational ancillary immunological study of a phase 3 clinical trial</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-26-00081-2-4c45715c/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-26-00081-2-4c45715c/</guid>
    <pubDate>Sat, 01 Aug 2026 00:00:00 GMT</pubDate>
    <description>The findings could inform immunological evaluation of RTS,S/AS01E by identifying antibody durability and maintenance, rather than peak responses alone, as potentially relevant correlates of vaccine efficacy.</description>
    <category>Malaria</category>
    <category>Vaccination</category>
    <category>Treatment</category>
    <category>Vaccine effectiveness</category>
    <category>Randomised controlled trial</category>
  </item>
  <item>
    <title>Durability of doxycycline effectiveness against gonorrhoea after implementation of post-exposure prophylaxis in southern California, USA: a retrospective, test-negative, observational study</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-26-00123-4-eac9400b/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-26-00123-4-eac9400b/</guid>
    <pubDate>Sat, 01 Aug 2026 00:00:00 GMT</pubDate>
    <description>Findings indicate that any gonorrhoea prevention benefit of doxycycline PEP may be short-lived in settings where tetracycline resistance expands, while protection against chlamydia and syphilis appears sustained beyond 2 years after implementation.</description>
    <category>Journal article</category>
  </item>
  <item>
    <title>Targeted Wastewater Surveillance during the World Athletics Championship, Oregon, USA, 2022</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-3201-eid3213-260537-2a842fb8/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-3201-eid3213-260537-2a842fb8/</guid>
    <pubDate>Sat, 01 Aug 2026 00:00:00 GMT</pubDate>
    <description>Incorporating pathogen tracking into existing monitoring frameworks may supply supplementary early warning indicators during mass assembly scenarios.</description>
    <category>SARS</category>
    <category>COVID-19</category>
    <category>Measles</category>
    <category>Influenza</category>
    <category>Hepatitis E</category>
    <category>Hepatitis A</category>
    <category>Surveillance</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Influenza Vaccine Effectiveness Against Outpatient Acute Respiratory Illness With Laboratory-confirmed Influenza, United States, 2024–2025 Season</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1093-cid-ciag437-411559fa/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1093-cid-ciag437-411559fa/</guid>
    <pubDate>Tue, 14 Jul 2026 00:00:00 GMT</pubDate>
    <description>The study provides a U.S. outpatient VE estimate for the 2024–2025 season, indicating vaccination reduced the risk of outpatient medically attended influenza by roughly one-third despite the predominance of A(H1N1)pdm09 and A(H3N2) viruses.</description>
    <category>Influenza</category>
    <category>Vaccination</category>
    <category>Vaccine effectiveness</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Assessment of Risk to the U.S. Population from the Ebola Disease Outbreak Caused by Bundibugyo Virus, 2026.</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-15585-mmwr-mm7522e2-ab9bf047/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-15585-mmwr-mm7522e2-ab9bf047/</guid>
    <pubDate>Thu, 11 Jun 2026 00:00:00 GMT</pubDate>
    <description>The evaluation outlines domestic preparedness thresholds and clarifies resource requirements for managing imported viral hemorrhagic fever scenarios.</description>
    <category>Ebola</category>
    <category>Hemorrhagic Fever</category>
    <category>Outbreak investigation</category>
    <category>Transmission dynamics</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Trends in funding for coronavirus vaccine research and development: implications for preparedness against future coronavirus threats</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-1038-s41541-026-01493-x-c5cef84f/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-1038-s41541-026-01493-x-c5cef84f/</guid>
    <pubDate>Tue, 26 May 2026 00:00:00 GMT</pubDate>
    <description>The findings suggest that reduced sustained investment in coronavirus vaccine research may weaken global preparedness and response capacity against future emergent coronavirus threats.</description>
    <category>COVID-19</category>
    <category>SARS</category>
    <category>Vaccination</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Increase in Travel-Associated and Locally Acquired Dengue Cases — United States, 2024</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-15585-mmwr-mm7518a1-a851abde/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-15585-mmwr-mm7518a1-a851abde/</guid>
    <pubDate>Thu, 14 May 2026 00:00:00 GMT</pubDate>
    <description>The authors highlight the need for enhanced prevention, clinical awareness, and tailored public health messaging for travelers to dengue-endemic areas, given the marked increase in reported cases and associated hospitalizations and deaths.</description>
    <category>Dengue</category>
    <category>Surveillance</category>
    <category>Travel medicine</category>
    <category>Journal article</category>
  </item>
  <item>
    <title>Knowledge, Attitudes, and Practices Regarding Avian Influenza Among Owners of Backyard Flocks — United States, July–December 2025</title>
    <link>https://globalinfectiousdisease.com/research/articles/10-15585-mmwr-mm7518a2-c95d2f76/</link>
    <guid isPermaLink="true">https://globalinfectiousdisease.com/research/articles/10-15585-mmwr-mm7518a2-c95d2f76/</guid>
    <pubDate>Thu, 14 May 2026 00:00:00 GMT</pubDate>
    <description>The abstract frames the findings as useful for risk communication and educational materials for backyard flock owners. It specifically relates these materials to protecting flocks, owners, and families from avian influenza.</description>
    <category>Influenza</category>
    <category>H5N1</category>
    <category>Journal article</category>
  </item>
</channel>
</rss>
